Demographic features of the patients. Except where indicated otherwise, values are mean ± SD.
| Characteristics | ETN, n = 71 | ETN + MTX, n = 76 | p |
|---|---|---|---|
| Age, yrs | 58.1 ± 12.6 | 56.6 ± 11.1 | 0.23 |
| Women, % | 87.3 | 80.3 | 0.27 |
| Body weight, kg | 51.0 ± 8.4 | 54.6 ± 11.3 | 0.057 |
| Disease duration, yrs | 10.6 ± 10.5 | 8.0 ± 7.6 | 0.21 |
| Positive rheumatoid factor, % | 91.5 | 86.7 | 0.43 |
| MTX dose, mg/wk | 7.0 ± 1.4 | 7.4 ± 1.1 | 0.099 |
| Total vdH-Sharp score, (median; IQR) | 114.5 ± 85.7 (94.5; 120.0) | 113.1 ± 85.6 (89.5; 91.0) | 0.99 |
| Estimated yearly progression, (median; IQR) | 17.7 ± 13.2 (13.9; 16.0) | 20.8 ± 18.2 (4.4; 12.2) | 0.45 |
| Erosion score, (median; IQR) | 55.6 ± 53.0 (43.5; 59.5) | 56.6 ± 54.4 (37.8; 53.0) | 0.80 |
| Joint space narrowing score, (median; IQR) | 58.9 ± 33.9 (54.0; 55.0) | 56.5 ± 32.9 (47.8; 41.4) | 0.79 |
ETN: etanercept; MTX: methotrexate; vdH: van der Heijde; IQR: interquartile range.